Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients.

Journal of Alzheimer's Disease : JAD
Xin ChengYong Shen

Abstract

We reported that tumor necrosis factor receptor I (TNFRI) is required for neuronal death induced by amyloid-beta protein in the Alzheimer's disease (AD) brain. However, whether TNF receptor subtypes are expressed and activated differentially in AD brains compared to non-demented brains remains unclear. Our studies on Western blot and ELISA measurements demonstrated that TNFRI levels are increased whereas TNFRII levels are decreased in AD brains compared to non-demented brains (p <0.05). Immunohistochemical results demonstrated that both TNFRI and TNFRII are expressed in neurons in AD and non-demented brains. However, in situ hybridization studies showed little change in the mRNA levels of either type of TNF receptor in the neurons of AD brains compared to non-demented brains. To examine whether different levels of TNF receptors in AD brains are correlated with the alteration of functional binding of TNF receptors, by using 125I-TNF-alpha binding technique, we found that, in AD brains, 125I-TNF-alpha binding affinity to TNFRI is increased, whereas binding affinity to TNFRII is decreased (p < 0.01). These studies reveal a novel observation of abnormal TNF receptor activation in AD brains. Differential TNF receptor protein levels ...Continue Reading

Citations

Oct 11, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ping HeYong Shen
Mar 24, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Petrus J W NaudéUlrich L M Eisel
Jul 11, 2013·BioMed Research International·Ana-Maria Enciu, Bogdan O Popescu
Jul 20, 2016·BioMed Research International·Peiqing ChenMing Yin
Jul 28, 2016·Frontiers in Aging Neuroscience·Shan JiangHong-Zhuan Chen
Dec 6, 2016·Nature Reviews. Immunology·Burkhard BecherJoan Goverman
Jan 29, 2017·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Yo Sup KimHyun Kim
Jun 6, 2017·Journal of Central Nervous System Disease·Rudy ChangRachita K Sumbria
Oct 21, 2017·Molecular Neurobiology·G MorrisB K Puri
Mar 15, 2011·Alzheimer Disease and Associated Disorders·Edward C Lauterbach
May 21, 2015·Nature Reviews. Neuroscience·Frank L HeppnerBurkhard Becher
Sep 14, 2012·Immunopharmacology and Immunotoxicology·Gholamreza Azizi, Abbas Mirshafiey
Feb 24, 2018·EMBO Molecular Medicine·Sophie SteelandRoosmarijn E Vandenbroucke
Jul 4, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Harald HampelZaven S Khachaturian
Feb 10, 2011·Clinical Chemistry and Laboratory Medicine : CCLM·Vida DemarinAna Marija Simundić
May 13, 2018·International Journal of Molecular Sciences·Sophie SteelandRoosmarijn E Vandenbroucke
Jan 30, 2019·Oxidative Medicine and Cellular Longevity·Alex France M MonteiroLuciana Scotti
Feb 20, 2019·Frontiers in Neuroscience·Natalia Ortí-CasañUlrich L M Eisel
Jan 29, 2016·Geriatrics & Gerontology International·Liara Rizzi, Matheus Roriz-Cruz
Nov 5, 2019·Frontiers in Neuroscience·Fernando Lucas-RuizMarta Agudo Barriuso
Jul 2, 2016·International Journal of Cancer. Journal International Du Cancer·Hannah R WardillStephen T Sonis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.